Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pegvisomant: structure and function.

S Pradhananga1, I Wilkinson, R J M Ross

  • 1Division of Clinical Sciences, University of Sheffield, Northern General Hospital, Sheffield S5 7AU, UK.

Journal of Molecular Endocrinology
|August 30, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Frailty: new horizons in older patients needing surgery.

Annals of the Royal College of Surgeons of England·2026
Same author

Corneal Deposits in a Jeweler: A case of ocular argyrosis.

Kathmandu University medical journal (KUMJ)·2026
Same author

Attosecond formation of charge-transfer-to-solvent states of aqueous ions probed using the core-hole-clock technique.

Nature communications·2024
Same author

Radiation damage by extensive local water ionization from two-step electron-transfer-mediated decay of solvated ions.

Nature chemistry·2023
Same author

Methods and considerations concerning cardiac output measurement in pregnant women: recommendations of the International Working Group on Maternal Hemodynamics.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2019
Same author

Request for Nominations for Members for the Committee on Laboratory Management of the Education and Management Division of IFCC.

EJIFCC·2018
Same journal

A Computational Systems Biology View on the Role of the Menstrual Cycle in Endocrine Health and Disease.

Journal of molecular endocrinology·2026
Same journal

Pancreatic β-cell aging in physiology and diabetes: emerging roles of m6A mRNA methylation.

Journal of molecular endocrinology·2026
Same journal

Neuroendocrine regulation of female fertility: the role of CNS-derived hormones.

Journal of molecular endocrinology·2026
Same journal

Hypothalamic neuropeptides as modulators of neural activity and behaviour.

Journal of molecular endocrinology·2026
Same journal

Massively parallel functional genomic assays in endocrinology: from promise to delivery.

Journal of molecular endocrinology·2026
Same journal

TSH promotes chemerin/CMKLR1-cAMP/ERK-DIO2 signaling in primary rat ependymal cells in vitro.

Journal of molecular endocrinology·2026
See all related articles

Pegvisomant, a modified growth hormone, effectively treats acromegaly. Its pegylation reduces receptor signaling while its prolonged clearance enhances clinical efficacy.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Molecular Biology

Background:

  • Pegvisomant is a pegylated mutant growth hormone (B2036).
  • B2036 exhibits altered binding affinities to the growth hormone receptor, enabling receptor dimerization but inhibiting downstream signaling.
  • Pegylation modifies B2036's pharmacokinetic and pharmacodynamic properties.

Purpose of the Study:

  • To elucidate the mechanism of action of pegvisomant.
  • To understand how pegylation impacts the antagonistic properties and clearance of B2036.
  • To highlight the clinical utility of pegvisomant in treating acromegaly.

Main Methods:

  • The study focuses on the molecular interactions of B2036 and pegvisomant with the growth hormone receptor.
  • Analysis of receptor dimerization and signaling pathways.

Related Experiment Videos

  • Pharmacokinetic evaluation comparing pegylated and unpegylated forms.

    • Main Results:

    • B2036 dimerizes the growth hormone receptor but blocks signal transduction.
    • Pegylation of B2036 reduces its intrinsic antagonistic activity.
    • Pegylation significantly decreases the clearance rate of B2036, leading to prolonged circulation time.

    Conclusions:

    • Despite lower direct antagonistic activity, pegvisomant's reduced clearance enhances its overall effectiveness.
    • Pegvisomant represents a clinically effective therapeutic agent for acromegaly.
    • The modified pharmacokinetic profile of pegvisomant is crucial for its therapeutic benefit.